地拉米定：对抗耐药结核病的新武器。
Delamanid: A new armor in combating drug-resistant tuberculosis.
作者信息
Xavier Alphienes Stanley, Lakshmanan Mageshwaran
机构信息
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
出版信息
J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121.
Abstract
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
摘要
人们一直在积极寻找新型抗结核药物，以解决结核病治疗中出现的耐药性、艾滋病毒合并感染以及药物相互作用风险等问题。地拉曼德是一种新型分枝杆菌细胞壁合成抑制剂，已获得欧洲药品管理局（EMA）有条件批准，用于治疗耐多药结核病。临床前和临床研究表明，地拉曼德效力高、药物相互作用风险低且耐受性较好。
相似文献
1
Delamanid: A new armor in combating drug-resistant tuberculosis.地拉米定：对抗耐药结核病的新武器。
J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121.
2
Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).地拉米定：从发现到用于治疗肺部耐多药结核病（MDR-TB）。
Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3.
3
Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.当其他抗结核治疗方案因耐药性或耐受性而失败时使用地拉米定。
Expert Opin Pharmacother. 2015 Feb;16(2):253-61. doi: 10.1517/14656566.2015.973853. Epub 2014 Oct 18.
4
Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.地拉米索用于治疗肺部耐多药结核病。
Drugs Today (Barc). 2015 Feb;51(2):117-23. doi: 10.1358/dot.2015.51.2.2245645.
5
Current Status of Delamanid in the Management of MDR Tuberculosis.德拉马尼在耐多药结核病治疗中的现状
J Assoc Physicians India. 2018 Jul;66(7):72-75.
6
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.儿童耐多药和广泛耐药结核病的治疗：贝达喹啉和德拉马尼的作用
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
7
An Experience with Delamanid in an XDR TB Case - Case Report.利奈唑胺治疗广泛耐药结核病 1 例报告
Infect Disord Drug Targets. 2021;21(4):637-639. doi: 10.2174/1871526520666200720113711.
8
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.德拉马尼：在耐多药结核病患者中的应用评价。
Drugs. 2015 Jan;75(1):91-100. doi: 10.1007/s40265-014-0331-4.
9
Management of drug resistantTB in patients with HIV co-infection.合并感染HIV的耐药结核病患者的管理。
Expert Opin Pharmacother. 2015;16(18):2737-50. doi: 10.1517/14656566.2015.1100169. Epub 2015 Oct 19.
10
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.人类结核病。III. 抗结核治疗的当前及未来方法
Curr Med Chem. 2016;23(21):2245-74. doi: 10.2174/0929867323666160504102636.
引用本文的文献
1
Evaluation of the In Vitro Activity of Bedaquiline, Delamanid, and Clofazimine Against Complex and Their Antibiofilm Potential.贝达喹啉、地拉曼尼德和氯法齐明对复合体的体外活性及其抗生物膜潜力的评估。
Pathogens. 2025 Jun 11;14(6):582. doi: 10.3390/pathogens14060582.
2
Strategic re-engineering of antibiotics.抗生素的战略重组
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
3
A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.人类免疫缺陷病毒相关结核病综合综述：临床挑战与管理进展
Cureus. 2024 Sep 6;16(9):e68784. doi: 10.7759/cureus.68784. eCollection 2024 Sep.
4
3,5-disubstituted pyridines with potent activity against drug-resistant clinical isolates.对耐药临床分离株具有强效活性的3,5-二取代吡啶。
Future Med Chem. 2024;16(22):2351-2369. doi: 10.1080/17568919.2024.2403963. Epub 2024 Oct 3.
5
Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis.治疗耐多药结核病的新型药物药理学
J Clin Tuberc Other Mycobact Dis. 2024 Jul 27;37:100470. doi: 10.1016/j.jctube.2024.100470. eCollection 2024 Dec.
6
Novel Prodrug Strategies for the Treatment of Tuberculosis.治疗结核病的新型前药策略。
Chem Asian J. 2024 Dec 2;19(23):e202400944. doi: 10.1002/asia.202400944. Epub 2024 Oct 24.
7
Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention.儿童耐多药结核病：关于流行病学、诊断、治疗及预防的实用最新进展
J Clin Tuberc Other Mycobact Dis. 2024 May 1;36:100449. doi: 10.1016/j.jctube.2024.100449. eCollection 2024 Aug.
8
Identification of Resistance to Common Antibiotics: An Overview of Current Methods and Techniques.常见抗生素耐药性的鉴定：当前方法与技术概述
Infect Drug Resist. 2024 Apr 12;17:1491-1506. doi: 10.2147/IDR.S457308. eCollection 2024.
9
Pediatric Drug-Resistant Tuberculosis: The Current and Future Prospects for Management and Prevention.儿童耐药结核病：管理与预防的现状及未来展望
Pathogens. 2023 Nov 20;12(11):1372. doi: 10.3390/pathogens12111372.
10
Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis.计算洞察结核分枝杆菌甲硫氨酰-tRNA 合成酶的底物诱导构象变化。
Protein J. 2023 Oct;42(5):533-546. doi: 10.1007/s10930-023-10135-3. Epub 2023 Jul 4.
本文引用的文献
1
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.德拉马尼可改善耐多药结核病的治疗结局，降低死亡率。
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
2
Delamanid for multidrug-resistant pulmonary tuberculosis.德拉马尼治疗耐多药肺结核。
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
3
Totally drug-resistant tuberculosis in India.印度的完全耐药结核病
Clin Infect Dis. 2012 Feb 15;54(4):579-81. doi: 10.1093/cid/cir889. Epub 2011 Dec 21.
4
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.利奈唑胺（OPC-67683）对痰涂片阳性肺结核患者的早期杀菌活性。
Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54. doi: 10.5588/ijtld.10.0616.
5
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.OPC-67683，一种硝基二氢咪唑并恶唑衍生物，在体外和小鼠体内对结核病有显著疗效。
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
Zotero 插件